CN111556750B - 线粒体功能障碍的改善剂和由线粒体功能障碍引起的疾病或症状的预防或治疗药物及其用途 - Google Patents

线粒体功能障碍的改善剂和由线粒体功能障碍引起的疾病或症状的预防或治疗药物及其用途 Download PDF

Info

Publication number
CN111556750B
CN111556750B CN201880085315.7A CN201880085315A CN111556750B CN 111556750 B CN111556750 B CN 111556750B CN 201880085315 A CN201880085315 A CN 201880085315A CN 111556750 B CN111556750 B CN 111556750B
Authority
CN
China
Prior art keywords
mitochondrial dysfunction
agent
diseases
mitochondrial
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880085315.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN111556750A (zh
Inventor
小坂仁
山形崇伦
神保恵理子
宫内彰彦
阿部高明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tohoku University NUC
Jichi Medical University
Original Assignee
Tohoku University NUC
Jichi Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tohoku University NUC, Jichi Medical University filed Critical Tohoku University NUC
Publication of CN111556750A publication Critical patent/CN111556750A/zh
Application granted granted Critical
Publication of CN111556750B publication Critical patent/CN111556750B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880085315.7A 2017-11-07 2018-11-07 线粒体功能障碍的改善剂和由线粒体功能障碍引起的疾病或症状的预防或治疗药物及其用途 Active CN111556750B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017214460A JP6958860B2 (ja) 2017-11-07 2017-11-07 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途
JP2017-214460 2017-11-07
PCT/JP2018/041354 WO2019093379A1 (ja) 2017-11-07 2018-11-07 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途

Publications (2)

Publication Number Publication Date
CN111556750A CN111556750A (zh) 2020-08-18
CN111556750B true CN111556750B (zh) 2023-05-26

Family

ID=66437831

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880085315.7A Active CN111556750B (zh) 2017-11-07 2018-11-07 线粒体功能障碍的改善剂和由线粒体功能障碍引起的疾病或症状的预防或治疗药物及其用途

Country Status (5)

Country Link
US (1) US11369615B2 (US07794700-20100914-C00152.png)
EP (1) EP3708161A4 (US07794700-20100914-C00152.png)
JP (1) JP6958860B2 (US07794700-20100914-C00152.png)
CN (1) CN111556750B (US07794700-20100914-C00152.png)
WO (1) WO2019093379A1 (US07794700-20100914-C00152.png)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7265926B2 (ja) 2019-04-26 2023-04-27 株式会社Ｎｔｔドコモ 通信制御装置および通信制御方法
WO2023006954A1 (en) 2021-07-30 2023-02-02 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Asenapine for use in cancer
CN118251379A (zh) 2021-11-15 2024-06-25 学校法人自治医科大学 铁死亡抑制剂及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102548986A (zh) * 2009-06-05 2012-07-04 链接医药公司 氨基吡咯烷酮衍生物及其用途
CA2920272A1 (en) * 2015-02-13 2016-08-13 Stealth Biotherapeutics Corp Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof to treat and prevent mitochondrial diseases and conditions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56166116A (en) 1980-05-26 1981-12-21 Showa Denko Kk Carcinostatic agent
AU5763600A (en) 1999-06-22 2001-01-09 Mitokor Compositions and methods for assaying subcellular conditions and processes usingenergy transfer
HU228783B1 (en) 2001-07-26 2013-05-28 Greenearth Cleaning Dry cleaning apparatus and method capable of utilizing a siloxane solvent
EP2865385B1 (en) * 2003-02-04 2016-11-16 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
PL2952191T3 (pl) * 2009-06-12 2019-02-28 Sunovion Pharmaceuticals Inc. Apomorfina w postaci do podawania podjęzykowego
JP2012041314A (ja) 2010-08-22 2012-03-01 Kanazawa Univ 脳腫瘍治療用キット及び脳腫瘍治療方法
HUE031633T2 (en) 2011-02-11 2017-07-28 Wista Lab Ltd Phenothiazine diaminium salts and their use
WO2012149478A2 (en) * 2011-04-28 2012-11-01 Serket Pharma, Llc Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
US9504692B2 (en) 2011-08-02 2016-11-29 Helmholtz Zentrum Munchen, Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Selective inhibition of MALT1 protease by phenothiazine derivatives
US20140275045A1 (en) 2013-03-15 2014-09-18 Edison Pharmaceuticals, Inc. Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
WO2015123365A1 (en) * 2014-02-11 2015-08-20 Mitokinin Llc Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
JP6763691B2 (ja) 2016-05-30 2020-09-30 上野製薬株式会社 熱可塑性樹脂組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102548986A (zh) * 2009-06-05 2012-07-04 链接医药公司 氨基吡咯烷酮衍生物及其用途
CA2920272A1 (en) * 2015-02-13 2016-08-13 Stealth Biotherapeutics Corp Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof to treat and prevent mitochondrial diseases and conditions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Apomorphine prevents myocardial ischemia/reperfusion-induced oxidative stress in the rat heart;IGOR KHALIULIN et al.;《Free Radical Biology & Medicine》;20040723;第37卷(第7期);第969-976页 *
IGOR KHALIULIN et al..Apomorphine prevents myocardial ischemia/reperfusion-induced oxidative stress in the rat heart.《Free Radical Biology & Medicine》.2004,第37卷(第7期),第969-976页. *
线粒体脑肌病伴乳酸酸中毒和卒中样发作综合征;陈春暖等;《临床神经病学杂志》;20111231;第24卷(第4期);第314-317页 *

Also Published As

Publication number Publication date
US11369615B2 (en) 2022-06-28
EP3708161A4 (en) 2021-08-18
JP2019085364A (ja) 2019-06-06
CN111556750A (zh) 2020-08-18
EP3708161A1 (en) 2020-09-16
US20200330475A1 (en) 2020-10-22
WO2019093379A1 (ja) 2019-05-16
JP6958860B2 (ja) 2021-11-02

Similar Documents

Publication Publication Date Title
CN111556750B (zh) 线粒体功能障碍的改善剂和由线粒体功能障碍引起的疾病或症状的预防或治疗药物及其用途
US20230381151A1 (en) Treating sickle cell disease with a pyruvate kinase r activating compound
EP1828167B1 (en) Acrylamide derivatives as antibiotic agents
US20140256803A1 (en) Tumor necrosis factor inhibitors
WO2000067734A2 (de) Verwendung von phthalazine-derivaten
US20200215001A1 (en) Compounds, compositions and methods for treating oxidative dna damage disorders
US11414419B2 (en) Substituted purines for the treatment of neurodegenerative and mitochondrial diseases
KR20170139047A (ko) 통증 치료
US20110166191A1 (en) 3-(2-amino-ethyl)-5-(3-cyclohexyl-propylidene)-thiazolidine-2,4-dione and its derivatives as multiple signaling pathway inhibitors and for the treatment of cancer
US20200061029A1 (en) Glaucocalyxin A Derivative, Pharmaceutically Acceptable Salt Thereof, Or Pharmaceutical Composition Thereof And Uses Thereof In Preparation Of Drugs For Treating Psoriasis
US8378112B2 (en) Glycyrrhetinic acid derivative and use thereof
US11147807B2 (en) Pharmaceutical composition containing DUSP1 inhibitor
US20030171379A1 (en) Methods of treating, preventing, or inhibiting inflammation with Mactanamide compounds
Dündar et al. Synthesis of some new 1-acylthiosemicarbazides and 1, 2, 4-triazol-5-thiones, and their analgesic and anti-inflammatory activities
US20180110775A1 (en) Compositions and methods for treating mitochondrial diseases
KR101855087B1 (ko) 칼콘 유도체 화합물, 이의 광학이성질체, 또는 이의 약학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 미토콘드리아의 산소 소모율 감소에 의해 야기되는 질환의 예방 또는 치료용 약학 조성물
KR20240012533A (ko) 자가면역, 동종면역, 염증성 및 미토콘드리아 질환 치료용 조성물 및 이의 용도
CN116249532A (zh) 使用Rho激酶抑制剂治疗血管性痴呆的方法
WO2015163431A1 (ja) 片頭痛治療剤
JP7360229B2 (ja) フェロトーシス阻害剤及びその用途
EP2939675B1 (en) Oct3 activity inhibitor containing imidazopyridine derivative as active component, and oct3 detection agent
US20230301947A1 (en) Compound for preventing and treating psychiatric disorders and use thereof
WO2023250332A1 (en) Compositions and methods involving isolated compounds
WO2013120896A1 (en) Compound for use in the prevention and/or treatment of a neurogenerative disease or a disease involving an activation of phosphodiesterase-4 (pde4)
ES2398268T3 (es) Derivados de fenantrolina triplemente sustituidos para el tratamiento de enfermedades o estados neurodegenerativos o hematológicos, o cáncer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant